

### IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

STATE OF OKLAHOMA, ex rel., MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA,	) } }
Plaintiff,	<b>\(\)</b>
v.	
PURDUE PHARMA L.P.; PURDUE PHARMA, INC.; THE PURDUE FREDERICK COMPANY; TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; JOHNSON & JOHNSON; JANSSEN PHARMACEUTICALS, INC.; ORTHO- McNEIL-JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICALS, INC., n/k/a JANSSEN PHARMACEUTICALS, INC.; ALLERGAN, PLC, f/k/a ACTAVIS PLC, f/k/a ACTAVIS, INC., f/k/a WATSON PHARMACEUTICALS, INC.; WATSON LABORATORIES, INC.; ACTAVIS LLC; and ACTAVIS PHARMA INC., f/k/a WATSON PHARMA, INC.,  Defendants.	Case No. CJ-2017-816  Honorable Thad Balkman  Special Discovery Master: William C. Hetherington, Jr.  STATE OF OKLAHOMA S.S. FILED  AUG 23 2018  In the office of the Court Clerk MARILYN WILLIAMS

## PURDUE'S RESPONSES AND OBJECTIONS TO PLAINTIFFS' NOTICE OF DEPOSITION

To: Corporate Representative State of Oklahoma

Via E-Mail

Michael Burrage
Reggie Whitten
Whitten Burrage
512 North Broadway Avenue, Suite 300
Oklahoma City, OK 73102
rmburrage@whittenburragelaw.com
rwhitten@whittenburragelaw.com

Via E-Mail

Abby Dillsaver
Ethan A. Shaner
Attorney General's Office
313 N.E. 21st Street
Oklahoma City, OK 73105
abby.dillsaver@oag.ok.gov
ethan.shaner@oag.ok.gov

### Via E-Mail

Bradley E. Beckworth
Jeffrey J. Angelovich
Lloyd "Trey" Nolan Duck, III
Andrew Pate
Lisa Baldin
Nix, Patterson & Roach, LLP
512 North Broadway Avenue, Suite 200
Oklahoma City, OK 73102
bbeckworth@nixlaw.com
jangelovich@npraustin.com
tduck@nixlaw.com
dpate@nixlaw.com
lbaldwin@nixlaw.com

### Via E-Mail

Glenn Coffee
Glenn Coffee & Associates, PLLC
915 North Robinson Avenue
Oklahoma City, OK 73102
gcoffee@glenncoffee.com

Purdue hereby responds and objects to the following deposition topic that the State noticed on August 8, 2018:

The Purdue Defendants' past and present ownership structure; financial status and financial health, including but not limited to information contained in any pro forma financial statements, such as gross revenue, liabilities, profits, and cash flow, for the past five years; distributions of any revenue and/or profits to owners in the past five years; and past and present formal and informal policies and procedures related to the distribution of any revenue and/or profits to owners.

This deposition topic does not comport with the ruling of the Special Discovery Master in the May 23, 2018 order.<sup>1</sup> Pursuant to that order, Purdue will designate a witness under 12 O.S. §3230(C)(5) to testify on the ownership structure for Purdue entities from and including 1996 onward, as well as documents produced to the State on June 8, 2018 (Bates numbered

Orders of Special Discovery Master on May 17, 2018 Motion Requests, May 23, 2018, Hetherington, W. at pp.4-5.

<sup>&</sup>lt;sup>1</sup> Judge Hetherington ruled, in relevant part:

<sup>&</sup>quot;Purdue's motion to quash is overruled and a protective order is entered only to the extent that allows Purdue to first provide to State the financial information requested from and including 1996 forward and the ownership structure for Purdue entities from and including 1996 forward. It is ordered that this document production be provided to State no later than 4 pm on June 8, 2018. Following that, Purdue shall designate a witness or witnesses to testify thereto with depositions to be completed no later than June 29th, 2018."

POK003284950-POK003285828). Purdue's witness is available for deposition on September 20, 26, or 27, 2018.

DATED: August 22, 2018.

Respectfully submitted,

Sanford C. Coats, OBA No. 18268 Joshua D. Burns, OBA No. 32967 CROWE & DUNLEVY, P.C.

Braniff Building

324 N. Robinson Ave., Ste. 100

Oklahoma City, OK 73102

Tel: (405) 235-7700 Fax: (405) 272-5269

sandy.coats@crowedunlevy.com joshua.burns@crowedunlevy.com

### Of Counsel:

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul A. LaFata Jonathan S. Tam DECHERT, LLP Three Bryant Park 1095 Avenue of the Americas New York, New York 10036 Tel: (212) 698-3500 Fax: (212) 698-3599 sheila.birnbaum@dechert.com mark.cheffo@dechert.com hayden.coleman@dechert.com paul.lafata@dechert.com jonathan.tam@dechert.com

Counsel for Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company Inc.

### CERTIFICATE OF SERVICE

I hereby certify that on this  $22^{nd}$  day of August 2018, I caused a true and correct copy of the following:

# PURDUE'S RESPONSES AND OBJECTION'S TO PLAINTIFFS' NOTICE OF DEPOSITION

to be served via email upon the counsel of record listed on the attached Service List.

Sanford C. Coats

#### SERVICE LIST

WHITTEN BURRAGE
Michael Burrage
Reggie Whitten
512 N. Broadway Avenue, Suite 300
Oklahoma City, OK 73102
mburrage@whittenburragelaw.com
rwhitten@whittenburragelaw.com
Counsel for Plaintiff the State of Oklahoma

NIX, PATTERSON & ROACH, LLP
Bradley E. Beckworth
Jeffrey J. Angelovich
Lloyd "Trey" Nolan Duck, III
Andrew Pate
Lisa Baldwin
512 N. Broadway Ave., Suite 200
Oklahoma City, OK 73102
bbeckworth@nixlaw.com
jangelovich@npraustin.com
tduck@nixlaw.com
dpate@nixlaw.com
lbaldwin@nixlaw.com
Counsel for Plaintiff the State of Oklahoma

ODOM, SPARKS & JONES PLLC Benjamin H. Odom John H. Sparks Michael W. Ridgeway David L. Kinney HiPoint Office Building 2500 McGee Drive Ste. 140 Oklahoma City, OK 73072 odomb@odomsparks.com sparksj@odomsparks.com ridgewaym@odomsparks.com kinneyd@odomsparks.com Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

OKLAHOMA OFFICE OF THE ATTORNEY GENERAL Mike Hunter Abby Dillsaver Ethan A. Shaner 313 NE 21st St Oklahoma City, OK 73105 abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov Counsel for Plaintiff the State of Oklahoma

GLENN COFFEE & ASSOCIATES, PLLC
Glenn Coffee
915 N. Robinson Ave.
Oklahoma City, OK 73102
gcoffee@glenncoffee.com
Counsel for Plaintiff the State of
Oklahoma

DECHERT, LLP Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul A. LaFata Jonathan S. Tam Three Bryant Park 1095 Avenue of the Americas New York, New York 10036 sheila.birnbaum@dechert.com mark.cheffo@dechert.com hayden.coleman@dechert.com paul.lafata@dechert.com jonathan.tam@dechert.com Counsel for Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company Inc.

### O'MELVENY & MYERS LLP

Charles C. Lifland Jennifer D. Cardelús David K. Roberts 400 S. Hope Street Los Angeles, CA 90071

clifland@omm.com

jcardelus@omm.com

droberts2@omm.com

Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

#### GABLEGOTWALS

Robert G. McCampbell Nicholas V. Merkley One Leadership Square, 15th Fl.

211 North Robinson

Oklahoma City, OK 73102-7255 RMcCampbell@Gablelaw.com

NMerkley@Gablelaw.com

Attorneys for Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a/ Watson Pharma, Inc.

### MORGAN, LEWIS & BOCKIUS LLP

Brian M. Ercole 200 S. Biscayne Blvd., Suite 5300 Miami, FL 33131

brian.ercole@morganlewis.com

Attorneys for Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a/ Watson Pharma, Inc.

O'MELVENY & MYERS LLP Stephen D. Brody 1625 Eye Street NW Washington, DC 20006 sbrody@omm.com Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

### MORGAN, LEWIS & BOCKIUS LLP

Steven A. Reed Harvey Bartle IV Rebecca Hillyer 1701 Market Street Philadelphia, PA 19103-2921 steven.reed@morganlewis.com harvey.bartle@morganlewis.com rebeccahillyer@morganlewis.com Attorneys for Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a/ Watson

Pharma, Inc.